Promis Neurosciences (QB) Stock Price - ARFXF

0.16
0.005 (3.23%)
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Promis Neurosciences Inc (QB) ARFXF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.005 3.23% 0.16 0.151 0.1638 0.151 0.155 16:19:46
Bid Price Ask Price Spread Spread % News
0.1482 0.27 0.1218 45.11% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
27 84,250 $ 0.158928 $ 13,390 178,063 0.115 - 0.3356
Last Trade Time Type Quantity Stock Price Currency
15:39:14 100 $ 0.16 USD

Promis Neurosciences (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 44.07M 275.41M $ -10.17M - - 231.08M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
5.29k $ - 0.00% - -

more financials information »

Promis Neurosciences (QB) News

Loading Messages....

Latest ARFXF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ARFXF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.15610.16710.1480.155523124,1000.00392.5%
1 Month0.160.17530.1480.1635675110,3090.000.0%
3 Months0.1380.180.1150.1532325194,4980.02215.94%
6 Months0.1640.200.1150.1573446161,000-0.004-2.44%
1 Year0.23760.33560.1150.18162155,012-0.0776-32.66%
3 Years0.1450.700.11030.2655631153,7530.01510.34%
5 Years0.0420.7030.01720.2510655137,1210.118280.95%

Promis Neurosciences (QB) Description

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts.


Your Recent History
USOTC
ARFXF
Promis Neu..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.